Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


The significance of IDH1 mutations in tumor-associated seizure in 60 Chinese patients with low-grade gliomas.

Liang R, Fan Y, Wang X, Mao Q, Liu Y.

ScientificWorldJournal. 2013 Nov 13;2013:403942. doi: 10.1155/2013/403942. eCollection 2013.


IDH1/2 mutation is associated with seizure as an initial symptom in low-grade glioma: A report of 311 Chinese adult glioma patients.

Zhong Z, Wang Z, Wang Y, You G, Jiang T.

Epilepsy Res. 2015 Jan;109:100-5. doi: 10.1016/j.eplepsyres.2014.09.012. Epub 2014 Nov 5.


IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas.

Liubinas SV, D'Abaco GM, Moffat BM, Gonzales M, Feleppa F, Nowell CJ, Gorelik A, Drummond KJ, O'Brien TJ, Kaye AH, Morokoff AP.

Epilepsia. 2014 Sep;55(9):1438-43. doi: 10.1111/epi.12662. Epub 2014 Jun 5.


Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.

Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, Ide T, Narita Y, Nishikawa R, Ueki K, Saito N.

Cancer Sci. 2012 Mar;103(3):587-92. doi: 10.1111/j.1349-7006.2011.02175.x. Epub 2012 Jan 13.


Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients.

Ren X, Cui X, Lin S, Wang J, Jiang Z, Sui D, Li J, Wang Z.

PLoS One. 2012;7(3):e32764. doi: 10.1371/journal.pone.0032764. Epub 2012 Mar 12.


Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.

Wang Y, Zhang T, Li S, Fan X, Ma J, Wang L, Jiang T.

Eur J Neurol. 2015 Feb;22(2):348-54. doi: 10.1111/ene.12578. Epub 2014 Oct 16.


Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY.

J Clin Oncol. 2009 Sep 1;27(25):4150-4. doi: 10.1200/JCO.2009.21.9832. Epub 2009 Jul 27.


IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas.

Qi ST, Yu L, Lu YT, Ou YH, Li ZY, Wu LX, Yao F.

Oncol Rep. 2011 Dec;26(6):1479-85. doi: 10.3892/or.2011.1428. Epub 2011 Aug 19.


A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).

Dahlrot RH, Kristensen BW, Hjelmborg J, Herrstedt J, Hansen S.

J Neurooncol. 2013 Sep;114(3):309-17. doi: 10.1007/s11060-013-1186-3. Epub 2013 Jul 2.


IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY.

Neurology. 2010 Oct 26;75(17):1560-6. doi: 10.1212/WNL.0b013e3181f96282.


Analysis of IDH1 and IDH2 mutations in Japanese glioma patients.

Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, Suzuki H, Tominaga T.

Cancer Sci. 2009 Oct;100(10):1996-8. doi: 10.1111/j.1349-7006.2009.01270.x.


Correlation between tumor-related seizures and molecular genetic profile in 103 Chinese patients with low-grade gliomas: a preliminary study.

Huang L, You G, Jiang T, Li G, Li S, Wang Z.

J Neurol Sci. 2011 Mar 15;302(1-2):63-7. doi: 10.1016/j.jns.2010.11.024. Epub 2010 Dec 24.


Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis.

Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhtari K, Wang XW, Loundou A, Chapon F, Pineau S, Ouafik L, Chinot O, Figarella-Branger D.

Acta Neuropathol. 2010 Dec;120(6):719-29. doi: 10.1007/s00401-010-0777-8. Epub 2010 Nov 16.


Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A.

Acta Neuropathol. 2009 Oct;118(4):469-74. doi: 10.1007/s00401-009-0561-9. Epub 2009 Jun 25.


Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival.

Yao Y, Chan AK, Qin ZY, Chen LC, Zhang X, Pang JC, Li HM, Wang Y, Mao Y, Ng HK, Zhou LF.

PLoS One. 2013 Jun 28;8(6):e67421. doi: 10.1371/journal.pone.0067421. Print 2013.


Clinical and molecular genetic factors affecting postoperative seizure control of 183 Chinese adult patients with low-grade gliomas.

You G, Huang L, Yang P, Zhang W, Yan W, Wang Y, Bao Z, Li S, Li S, Li G, Jiang T.

Eur J Neurol. 2012 Feb;19(2):298-306. doi: 10.1111/j.1468-1331.2011.03509.x. Epub 2011 Sep 6.


[IDH1/2 mutations in gliomas].

Nobusawa S, Yokoo H.

Brain Nerve. 2011 Dec;63(12):1378-86. Review. Japanese.


Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.

Wang XW, Boisselier B, Rossetto M, Marie Y, Idbaih A, Mokhtari K, Gousias K, Hoang-Xuan K, Delattre JY, Simon M, Labussière M, Sanson M.

Cancer. 2013 Feb 15;119(4):806-13. doi: 10.1002/cncr.27798. Epub 2012 Nov 26.


Distinct IDH1/IDH2 mutation profiles in purely insular versus paralimbic WHO Grade II gliomas.

Gozé C, Mansour L, Rigau V, Duffau H.

J Neurosurg. 2013 Apr;118(4):866-72. doi: 10.3171/2012.11.JNS121100. Epub 2013 Jan 18.


IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas.

Shibahara I, Sonoda Y, Kanamori M, Saito R, Yamashita Y, Kumabe T, Watanabe M, Suzuki H, Kato S, Ishioka C, Tominaga T.

Int J Clin Oncol. 2012 Dec;17(6):551-61. doi: 10.1007/s10147-011-0323-2. Epub 2011 Oct 6.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk